Clinical Trials
28 trialsNCT06625515 2026-02-24
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Phase 1 Terminated
NCT06457997 2026-01-29
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Phase 1 Terminated
NCT05194072 2026-01-09
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
Phase 1 Terminated
NCT03746431 2026-01-07
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
Phase 1 Terminated
NCT05252416 2025-11-28
(VELA) Study of BLU-222 in Advanced Solid Tumors
Blueprint Medicines Corporation
Phase 1 Terminated
NCT04272034 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT06264921 2025-09-25
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Phase 1 Terminated
NCT04458259 2025-08-28
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT06299163 2025-07-23
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
Phase 1 Terminated
NCT05274451 2025-07-01
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
Phase 1 Terminated
NCT03277482 2025-05-31
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT04152018 2025-05-28
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT05067972 2025-05-06
C4431001
Pfizer
Phase 1 Terminated
NCT04209465 2025-04-17
MasterKey-01
Black Diamond Therapeutics, Inc.
Phase 1 Terminated
NCT05229900 2025-02-10
A Study of SGN-ALPV in Advanced Solid Tumors
Seagen Inc.
Phase 1 Terminated
NCT04665921 2025-02-07
A Study of SGN-STNV in Advanced Solid Tumors
Seagen Inc.
Phase 1 Terminated
NCT05107739 2024-05-03
A Study of DeTIL-0255 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Terminated
NCT04586335 2024-03-21
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Haihe Biopharma Co., Ltd.
Phase 1 Terminated
NCT05332483 2023-11-03
MA-EEC
Sunnybrook Health Sciences Centre
Phase 1 Terminated
NCT05069935 2023-09-21
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT04178460 2022-06-01
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
Zai Lab (Hong Kong), Ltd.
Phase 1 Terminated
NCT03924245 2022-04-04
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
Vanderbilt-Ingram Cancer Center
Phase 1 Terminated
NCT02189174 2021-12-03
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
Novartis
Phase 1 Terminated
NCT02476955 2020-09-30
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT03138408 2019-05-14
SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers
AbbVie
Phase 1 Terminated
NCT02589366 2018-10-15
Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium
University of California, San Diego
Phase 1 Terminated
NCT01401829 2015-05-12
Psychosocial Benefits of Exercise in Endometrial Cancer Survivors
University of Alabama at Birmingham
Phase 1 Terminated
NCT00689065 2013-11-01
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Calando Pharmaceuticals
Phase 1 Terminated